Phathom Pharmaceuticals’ $130 Million Public Offering of Common Stock

Latham & Watkins advises Phathom Pharmaceuticals in pricing of US$130 million public offering of common stock.Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Marco Zingaro

This content is for Standard 1 Year members only.
Login Join Now